Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on May 12, 2023 10:14am
128 Views
Post# 35445263

RE:Why

RE:WhyWe did not vote for 2022 bonuses as those were already paid (technically we voted for the board in the prior year and they have the freedom to approve the bonuses). We voted for the bonus plan so that we can retain the employees who may well transform TH-1902 into something we and all those suffering from some forms of cancer will be very thankful for. If TH-1902 gets past  phase 1b successfully, things will start looking up for THTX. So, to maximize the chances of TH-1902 possibly being a success, you do what you can to keep it on track. Losing key employees (notably Christian) would likely not be the best idea right now. So, you try to put the ugly past behind you and stay focused on turning this lemon into some tasty lemonade.

Trogarzon wrote: So we collectively voted them 100%+ bonuses in 2022 and for an option plan set at a max of 17% of the float. Why please. For delevering deficits and financial precarity.  I'm not inventing this, it was in the proxy.


<< Previous
Bullboard Posts
Next >>